COVID 19 drug Paxlovid

Published On 2022-01-01 11:08 GMT   |   Update On 2022-01-01 11:08 GMT

As the number of Omicron cases continues to increase in India and worldwide, recently approved antiviral pills could be a game-changer for the most vulnerable. However, the experts have cautioned that some of these new medications may not be safe for everyone and might require careful monitoring by doctors and pharmacists. The FDA had recently given approval for Emergency...

Login or Register to read the full article

As the number of Omicron cases continues to increase in India and worldwide, recently approved antiviral pills could be a game-changer for the most vulnerable. However, the experts have cautioned that some of these new medications may not be safe for everyone and might require careful monitoring by doctors and pharmacists.

The FDA had recently given approval for Emergency Use Authorisation (EUA) Paxlovid, developed by Pfizer Inc for treating mild-to-moderate Covid-19 in adults and children 12 years and older, who are likely to be at greater risk for severe infection. This came after the fact that in clinical trials Paxlovid was shown to reduce COVID-19-related hospitalization or death from any cause by 89% compared to placebo in patients treated within three days of symptom onset.


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News